Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.
Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.
Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.
Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Northwest Biotherapeutics Volatility Related Terms
STU:NBYB vs LCTX, VRXA, ABEO: Volatility Comparison
For the Biotechnology subindustry, Northwest Biotherapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Northwest Biotherapeutics Volatility vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Volatility distribution charts can be found below:
* The bar in red indicates where Northwest Biotherapeutics's Volatility falls into.
The annualized volatility is calculated as following:
σA
=
σM
*
√12
=
√ 1/(n-1) ∑(Ri - R')^2
*
√12
Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (STU:NBYB) has a Volatility of 60.88% as of Jul. 21, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Volatility too high?
Northwest Biotherapeutics' current Volatility is 60.88%. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Volatility compare to LCTX and VRXA?
Northwest Biotherapeutics' Volatility of 60.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Volatility is 60.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Northwest Biotherapeutics (STU:NBYB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.24, compared to a current price of €0.15 — trading 37.5% below its estimated fair value. The current Volatility is 60.88%. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Northwest Biotherapeutics (STU:NBYB), the current Volatility is 60.88% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Northwest Biotherapeutics (STU:NBYB) Overvalued in 2026?
Based on GuruFocus' analysis, Northwest Biotherapeutics stock appears to be undervalued.
The current stock price of €0.15 is trading 37.5% below its estimated GF Value™ of €0.24.
GuruFocus considers Northwest Biotherapeutics to be Possible Value Trap.
Key valuation signals for STU:NBYB:
Volatility: 60.88%
GF Value™: €0.24 vs. price of €0.15 (37.5% below fair value)
No single metric tells the full story. See the STU:NBYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score
Get the complete analysis for STU:NBYB
Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:NBYB has been successfully added to your 
